WO2004050828A3 - Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer - Google Patents
Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer Download PDFInfo
- Publication number
- WO2004050828A3 WO2004050828A3 PCT/US2002/038264 US0238264W WO2004050828A3 WO 2004050828 A3 WO2004050828 A3 WO 2004050828A3 US 0238264 W US0238264 W US 0238264W WO 2004050828 A3 WO2004050828 A3 WO 2004050828A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- useful
- detection
- treatment
- nucleic acid
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002352976A AU2002352976B2 (en) | 2002-11-27 | 2002-11-27 | Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
PCT/US2002/038264 WO2004050828A2 (fr) | 2002-11-27 | 2002-11-27 | Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer |
CA2503346A CA2503346C (fr) | 2002-11-27 | 2002-11-27 | Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer |
EP02789937A EP1565200A4 (fr) | 2002-11-27 | 2002-11-27 | Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer |
JP2004557078A JP2006508163A (ja) | 2002-11-27 | 2002-11-27 | 癌の処置および検出において有用な24p4c12と称される、核酸および対応タンパク質 |
IL167892A IL167892A (en) | 2002-11-27 | 2005-04-06 | Nucleic acid and protein entitled 24p4c12 and compositions containing the same and uses thereof |
AU2008200628A AU2008200628B2 (en) | 2002-11-27 | 2008-02-08 | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
AU2009208065A AU2009208065B2 (en) | 2002-11-27 | 2009-08-07 | Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2002/038264 WO2004050828A2 (fr) | 2002-11-27 | 2002-11-27 | Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004050828A2 WO2004050828A2 (fr) | 2004-06-17 |
WO2004050828A3 true WO2004050828A3 (fr) | 2004-12-09 |
Family
ID=32467113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/038264 WO2004050828A2 (fr) | 2002-11-27 | 2002-11-27 | Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1565200A4 (fr) |
JP (1) | JP2006508163A (fr) |
AU (3) | AU2002352976B2 (fr) |
CA (1) | CA2503346C (fr) |
IL (1) | IL167892A (fr) |
WO (1) | WO2004050828A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009033094A2 (fr) * | 2007-09-07 | 2009-03-12 | Agensys, Inc. | Anticorps et molécules apparentées qui se lient aux protéines 24p4c12 |
EP2403524A4 (fr) * | 2009-03-06 | 2012-09-26 | Agensys Inc | Conjugues anticorps-medicament (adc) se liant aux proteines 24p4c12 |
JP2013049646A (ja) * | 2011-08-30 | 2013-03-14 | Tokyo Medical Univ | 癌治療剤 |
BR112018006263A2 (pt) | 2015-10-02 | 2018-10-16 | Memorial Sloan Kettering Cancer Center | inibidor de tonsl, molécula pequena, uso de uma molécula pequena ou de um inibidor, cristal tridimensional, métodos para selecionar ou desenhar uma molécula pequena, para identificar um inibidor de ligação de ard de tonsl à histona h4, para predizer o efeito de inibição de tonsl e para identificar um inibidor de tonsl e/ou determinar o efeito inibitório de um inibidor putativo de tonsl, sequência de polinucleotídeo ou sequência de aminoácidos isolada, e, polipeptídeo mutante de tonsl. |
JP7438662B2 (ja) | 2016-01-25 | 2024-02-27 | ジェネンテック, インコーポレイテッド | T細胞依存性二重特異的抗体をアッセイするための方法 |
EP3617312A4 (fr) * | 2017-04-28 | 2021-04-07 | Hoyu Co., Ltd. | Antigène d'allergie et épitope associé |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030147904A1 (en) * | 1999-04-12 | 2003-08-07 | Afar Daniel E. | Novel 13-transmembrane protein expressed in prostate cancer |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
AU625013B2 (en) | 1989-11-03 | 1992-06-25 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
SE9002480D0 (sv) | 1990-07-23 | 1990-07-23 | Hans Lilja | Assay of free and complexed prostate-specific antigen |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
JP3926839B2 (ja) | 1993-09-14 | 2007-06-06 | エピミューン,インコーポレイティド | 万能dr−結合性ペプチドを用いる免疫応答の改変 |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5919652A (en) | 1994-11-09 | 1999-07-06 | The Regents Of The University Of California | Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
CU22559A1 (es) | 1996-01-17 | 1999-05-03 | Ct Ingenieria Genetica Biotech | Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión |
JP2001504799A (ja) | 1996-03-11 | 2001-04-10 | エピミューン インコーポレイテッド | Hla分子への結合アフィニティーが増加したペプチド |
WO1998004720A1 (fr) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Procedes et reactifs destines a l'immunisation genetique |
US5840501A (en) | 1996-10-25 | 1998-11-24 | Bayer Corporation | Determination of cPSA |
WO1999006550A2 (fr) * | 1997-08-01 | 1999-02-11 | Genset | Marqueurs sequences 5' exprimes pour proteines secretees exprimees dans la prostate |
AU780061B2 (en) * | 1999-04-12 | 2005-02-24 | Agensys, Inc. | Transmembrane protein expressed in prostate and other cancers |
JP2004500814A (ja) * | 1999-12-23 | 2004-01-15 | インサイト・ゲノミックス・インコーポレイテッド | 輸送体及びイオンチャネル |
-
2002
- 2002-11-27 EP EP02789937A patent/EP1565200A4/fr not_active Withdrawn
- 2002-11-27 AU AU2002352976A patent/AU2002352976B2/en not_active Expired
- 2002-11-27 WO PCT/US2002/038264 patent/WO2004050828A2/fr active Application Filing
- 2002-11-27 JP JP2004557078A patent/JP2006508163A/ja active Pending
- 2002-11-27 CA CA2503346A patent/CA2503346C/fr not_active Expired - Lifetime
-
2005
- 2005-04-06 IL IL167892A patent/IL167892A/en active IP Right Grant
-
2008
- 2008-02-08 AU AU2008200628A patent/AU2008200628B2/en not_active Expired
-
2009
- 2009-08-07 AU AU2009208065A patent/AU2009208065B2/en not_active Expired
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030147904A1 (en) * | 1999-04-12 | 2003-08-07 | Afar Daniel E. | Novel 13-transmembrane protein expressed in prostate cancer |
Non-Patent Citations (1)
Title |
---|
See also references of EP1565200A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU2008200628B2 (en) | 2009-05-07 |
AU2008200628A1 (en) | 2008-03-06 |
AU2002352976A1 (en) | 2004-06-23 |
CA2503346A1 (fr) | 2004-06-17 |
CA2503346C (fr) | 2014-03-18 |
IL167892A (en) | 2012-06-28 |
AU2009208065A1 (en) | 2009-08-27 |
EP1565200A4 (fr) | 2009-06-24 |
AU2002352976B2 (en) | 2007-11-08 |
AU2009208065B2 (en) | 2012-05-24 |
WO2004050828A2 (fr) | 2004-06-17 |
EP1565200A2 (fr) | 2005-08-24 |
JP2006508163A (ja) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003022995A3 (fr) | Acide nucleique et proteine correspondante designes par steap-1 utiles dans le traitement et la detection du cancer | |
WO2003040340A3 (fr) | Acide nucleique et proteine correspondante 161p2f10b utiles dans le traitement et le depistage du cancer | |
WO2004016799A3 (fr) | Acides nucleiques et proteines correspondantes intitulees 191p4d12(b) utilises dans le traitement et la detection du cancer | |
ZA200509606B (en) | Prostate stem cell antigen (PSCA) variants and subsequences thereof | |
WO2003050255A3 (fr) | Acide nucleique et proteine correspondante appelee 193p1e1b utile dans le traitement et la detection du cancer | |
IL181218A0 (en) | Nucleic acids and corresponding 58p1d12 proteins for use in the detection and treatment of cancer | |
WO2005118864A3 (fr) | Anticorps et molecules apparentees qui se lient aux proteines d'antigene des cellules souches de prostate (proteines de psca) | |
CY1113064T1 (el) | Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη με τιτλο 184ρ1ε2 χρησιμα στη θεραπεια και ανιχνευση καρκινου | |
WO2004098515A3 (fr) | Acides nucleiques et proteines correspondantes appelees 109p1d4 utiles dans le traitement et la detection du cancer | |
WO2002072785A3 (fr) | Acide nucleique et proteine correspondante denommes 125p5c8 utiles dans le traitement et la detection de cancers | |
WO2004067716A3 (fr) | Acides nucleiques et proteines correspondantes dites 254p1d6b utiles pour la detection et le traitement du cancer | |
WO2002060953A3 (fr) | Acide nucleique et proteine transporteur de zinc codee intitules 108p5h8 utiles dans le traitement et la detection du cancer | |
WO2002083928A3 (fr) | Acide nucleique et proteine correspondante intitule 158p3d2 utiles dans le traitement et la detection du cancer | |
WO2006055004A8 (fr) | Acides nucléiques et protéines correspondantes désignés par 158p3d2, et pouvant être employés dans le traitement et la détection de cancers | |
WO2004050828A3 (fr) | Acide nucleique 24p4c12 et proteine correspondante utilises dans le traitement et la detection du cancer | |
WO2002092842A3 (fr) | Acides nucleiques et proteines correspondantes dits 101p3a11 ou phor-1 servant au traitement et a la detection de cancers | |
WO2002095009A3 (fr) | Acide nucleique et proteine correspondante, appelee 121p1f1, utilisee dans le traitement et le depistage du cancer | |
WO2004021977A3 (fr) | Acide nucleique et proteine correspondante denommes 98p4b6, pour traitement et detection du cancer | |
WO2003085081A3 (fr) | Acide nucleique et proteine correspondante appelee 238p1b2 utile dans le traitement et la detection du cancer | |
WO2002083068A8 (fr) | Acide nucleique et proteine correspondante appele 121p2a3 utile pour le traitement et la detection des cancers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 167892 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2503346 Country of ref document: CA Ref document number: 2002789937 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002352976 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004557078 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002789937 Country of ref document: EP |